Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on assets (ROA) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -25.32%.
RETURN ON ASSETS (ROA)
N/A
RETURN ON ASSETS (ROA) AVG TTM
-37.02%
RETURN ON ASSETS (ROA) AVG 3Y
-41.41%
RETURN ON ASSETS (ROA) AVG 5Y
-41.74%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
CytoMed Therapeutics Limited
Market Cap
$11.95M
Return on Assets (ROA)
N/A
TTM Avg
-37.02%
3Y Avg
-41.41%
5Y Avg
-41.74%
Market Cap
$11.94M
Return on Assets (ROA)
-13.01%
TTM Avg
-15.22%
3Y Avg
-24.53%
5Y Avg
-20.43%
Market Cap
$12.46M
Return on Assets (ROA)
-47.98%
TTM Avg
-31.15%
3Y Avg
-42.27%
5Y Avg
-34.21%
Market Cap
$11.42M
Return on Assets (ROA)
-198.70%
TTM Avg
-189.50%
3Y Avg
-187.22%
5Y Avg
-200.18%
Market Cap
$11.41M
Return on Assets (ROA)
-26.45%
TTM Avg
-58.62%
3Y Avg
-47.64%
5Y Avg
-51.16%
Market Cap
$12.63M
Return on Assets (ROA)
-49.12%
TTM Avg
-29.80%
3Y Avg
-67.98%
5Y Avg
-117.36%
Market Cap
$11.21M
Return on Assets (ROA)
-46.21%
TTM Avg
-17.41%
3Y Avg
-49.70%
5Y Avg
-52.01%
Market Cap
$11.01M
Return on Assets (ROA)
-77.94%
TTM Avg
-178.68%
3Y Avg
-1009.31%
5Y Avg
-2782.57%
Market Cap
$10.86M
Return on Assets (ROA)
-154.89%
TTM Avg
-40.68%
3Y Avg
-87.98%
5Y Avg
-439.28%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CytoMed Therapeutics Limited (GDTC) | $11.95M | N/A | -37.02% | -41.41% | -41.74% |
| IRIDEX Corporation (IRIX)vs › | $11.94M | -13.01% | -15.22% | -24.53% | -20.43% |
| Cytosorbents Corporation (CTSO)vs › | $12.46M | -47.98% | -31.15% | -42.27% | -34.21% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.42M | -198.70% | -189.50% | -187.22% | -200.18% |
| Biofrontera Inc. (BFRI)vs › | $11.41M | -26.45% | -58.62% | -47.64% | -51.16% |
| Dare Bioscience, Inc. (DARE)vs › | $12.63M | -49.12% | -29.80% | -67.98% | -117.36% |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.21M | -46.21% | -17.41% | -49.70% | -52.01% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.01M | -77.94% | -178.68% | -1009.31% | -2782.57% |
| BioVie Inc. (BIVI)vs › | $10.86M | -154.89% | -40.68% | -87.98% | -439.28% |
| Cerenome, Inc. (CNSY)vs › | $10.74M | -185.94% | -166.39% | -133.67% | -110.62% |
ROA
N/A
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -49.05% |
| 2024-12-31 | -25.00% |
| 2023-12-31 | -33.41% |
| 2022-12-31 | -58.18% |
| 2021-12-31 | -34.01% |
| 2020-12-31 | -50.79% |
| 2019-12-31 | -29.17% |
